BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schad F, Thronicke A, Steele ML, Merkle A, Matthes B, Grah C, Matthes H. Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis. PLoS One. 2018;13:e0203058. [PMID: 30148853 DOI: 10.1371/journal.pone.0203058] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Lampignano R, Kloten V, Krahn T, Schlange T. Integrating circulating miRNA analysis in the clinical management of lung cancer: Present or future? Molecular Aspects of Medicine 2020;72:100844. [DOI: 10.1016/j.mam.2020.100844] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Thronicke A, Reinhold T, von Trott P, Grah C, Matthes B, Matthes H, Schad F. Cost-effectiveness of real-world administration of chemotherapy and add-on Viscum album L. therapy compared to chemotherapy in the treatment of stage IV NSCLC patients. PLoS One 2020;15:e0236426. [PMID: 32716969 DOI: 10.1371/journal.pone.0236426] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Zerunian M, Caruso D, Zucchelli A, Polici M, Capalbo C, Filetti M, Mazzuca F, Marchetti P, Laghi A. CT based radiomic approach on first line pembrolizumab in lung cancer. Sci Rep 2021;11:6633. [PMID: 33758304 DOI: 10.1038/s41598-021-86113-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
4 Choi JY, Ji W, Choi CM, Chung C, Noh JM, Park CK, Oh IJ, Yoon HI, Kim HR, Kim HY, Yeo CD, Jang SH; Public Relation Committee of the Korean Association for Lung Cancer. Awareness and Use of Complementary and Alternative Medicine in Korean Lung Cancer Patients. Tuberc Respir Dis (Seoul) 2021;84:105-14. [PMID: 33287469 DOI: 10.4046/trd.2020.0098] [Reference Citation Analysis]
5 Song C, Wei XY, Qiu ZD, Gong L, Chen ZY, Ma Y, Shen Y, Zhao YJ, Wang WH, Lai CJ, Yang B. Exploring the resources of the genus Viscum for potential therapeutic applications. J Ethnopharmacol 2021;277:114233. [PMID: 34044077 DOI: 10.1016/j.jep.2021.114233] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 López-moreno M, Garcés-rimón M, Miguel M. Antinutrients: Lectins, goitrogens, phytates and oxalates, friends or foe? Journal of Functional Foods 2022;89:104938. [DOI: 10.1016/j.jff.2022.104938] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Thronicke A, Matthes B, von Trott P, Schad F, Grah C. Overall Survival of Nonmetastasized NSCLC Patients Treated With Add-On Viscum album L: A Multicenter Real-World Study. Integr Cancer Ther 2020;19:1534735420940384. [PMID: 32856476 DOI: 10.1177/1534735420940384] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Chen Q, Wright F, Duncan L, Huntley A. Profiling mistletoe therapy research and identifying evidence gaps: A systematic review of conditions treated, mode of application and outcomes. European Journal of Integrative Medicine 2022;49:101392. [DOI: 10.1016/j.eujim.2021.101392] [Reference Citation Analysis]
9 Gibson AJW, Box A, Dean ML, Elegbede AA, Hao D, Sangha R, Bebb DG. Retrospective Real-World Outcomes for Patients With ALK-Rearranged Lung Cancer Receiving ALK Receptor Tyrosine Kinase Inhibitors. JTO Clin Res Rep 2021;2:100157. [PMID: 34590010 DOI: 10.1016/j.jtocrr.2021.100157] [Reference Citation Analysis]
10 Oei SL, Thronicke A, Schad F. Mistletoe and Immunomodulation: Insights and Implications for Anticancer Therapies. Evid Based Complement Alternat Med 2019;2019:5893017. [PMID: 31118962 DOI: 10.1155/2019/5893017] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
11 Thronicke A, Reinhold T, von Trott P, Matthes H, Schad F. Cost-Effectiveness of Real-World Administration of Concomitant Viscum album L. Therapy for the Treatment of Stage IV Pancreatic Cancer. Evid Based Complement Alternat Med 2020;2020:3543568. [PMID: 32256640 DOI: 10.1155/2020/3543568] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Li Y, Li Y, Xia J, Yang Q, Chen Y, Sun H. 3'-Sulfo-TF Antigen Determined by GAL3ST2/ST3GAL1 Is Essential for Antitumor Activity of Fungal Galectin AAL/AAGL. ACS Omega 2021;6:17379-90. [PMID: 34278124 DOI: 10.1021/acsomega.1c01544] [Reference Citation Analysis]
13 Bartelme RR. Anthroposophic Medicine: A Short Monograph and Narrative Review-Foundations, Essential Characteristics, Scientific Basis, Safety, Effectiveness and Misconceptions. Glob Adv Health Med 2020;9:2164956120973634. [PMID: 33457106 DOI: 10.1177/2164956120973634] [Reference Citation Analysis]
14 Kim DK, Kim BR, Jeong JS, Baek YH. Analysis of intrahepatic sarcomatoid cholangiocarcinoma: Experience from 11 cases within 17 years. World J Gastroenterol 2019; 25(5): 608-621 [PMID: 30774275 DOI: 10.3748/wjg.v25.i5.608] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
15 Kiene H. Das Gegenteil von Evidence-Based Journalism: Der MedWatch-Artikel zum "vermeintlichen Mistel-Wunder". Complement Med Res 2020;27:117-21. [PMID: 32208398 DOI: 10.1159/000506391] [Reference Citation Analysis]
16 Bhutia SK, Panda PK, Sinha N, Praharaj PP, Bhol CS, Panigrahi DP, Mahapatra KK, Saha S, Patra S, Mishra SR, Behera BP, Patil S, Maiti TK. Plant lectins in cancer therapeutics: Targeting apoptosis and autophagy-dependent cell death. Pharmacol Res 2019;144:8-18. [PMID: 30951812 DOI: 10.1016/j.phrs.2019.04.001] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 12.7] [Reference Citation Analysis]
17 Thronicke A, von Trott P, Kröz M, Grah C, Matthes B, Schad F. Health-Related Quality of Life in Patients with Lung Cancer Applying Integrative Oncology Concepts in a Certified Cancer Centre. Evid Based Complement Alternat Med 2020;2020:5917382. [PMID: 32454866 DOI: 10.1155/2020/5917382] [Reference Citation Analysis]